Arcutis Biotherapeutics (ARQT) presents a deeply negative liquidation posture as of March 31, 2026, consistent with prior periods. Under the liquidation lens, recoverable assets are dominated by liquid instruments—cash and cash equivalents of $34.8M (100% recovery), restricted cash of $0.3M, and marketable securities of $189.2M (fair value, nearly all AFS debt securities classified as current; recovery treated at 100% given exchange-listed, investment-grade instruments with minimal unrealized loss of $0.3M). Accounts receivable of $144.4M receives a 90-95% haircut, yielding approximately $130M-$137M. Inventory of $37.4M at a 60% recovery rate yields approximately $22M. PP&E of $1.0M net book value recovers perhaps $0.5M-$0.7M at 50-70%. Intangible assets of $14.3M (primarily the AstraZeneca roflumilast license, being amortized over 10 years from first commercial sale in 2022) receive zero recovery under the liquidation lens. Operating lease ROU asset of $4.4M also receives zero recovery. Total estimated recoverable asset value: approximately $390M-$400M. Against this, liabilities stand at face value of $270.4M, including: current liabilities of $163.2M (accrued liabilities $137.0M, accounts payable $18.3M, current portion of LTD $8.0M); non-current long-term debt carrying value of $109.4M (gross principal $100M plus accrued final fee of $9.2M, less $0.8M unamortized issuance costs); non-current operating lease liability $5.3M; other non-current liabilities $0.4M. The SLR term loan is secured by substantially all assets including IP, and in a liquidation/acceleration scenario the borrower would owe principal $100M plus the $6.95M final fee (on the 2024 partial prepayment portion, due January 1, 2027), plus the $1.0M prepayment penalty due June 30, 2026, plus applicable prepayment premiums of 2-3% depending on timing. The aggregate debt obligation at liquidation could reach $107M-$110M. Residual equity recovery is marginally positive to marginally negative depending on AR collection assumptions and liquidation expense loads. This is consistent with MFFAIS's reported OLV of negative $53M and CLV of negative $235M—the CLV figure implies a much deeper haircut scenario reflecting IP and other asset impairment. Key changes from the prior filing (10-K, December 31, 2025): inventory increased sharply from $22.6M to $37.4M (+65%), a material build that adds liquidation drag at the 60% haircut; accrued liabilities rose from $116.3M to $137.0M (+18%), driven by accrued sales deductions up $21.2M and a new $10.0M Ducentis milestone accrual; marketable securities increased from $178.1M to $189.2M. The Ducentis milestone ($10M expensed in Q1 2026, $9.2M to be settled via promissory notes bearing no interest callable in 7 months) represents a new concrete near-term cash obligation not present in the prior period. Manufacturing purchase commitments are described in MD&A as unchanged, and are not separately XBRL-tagged. The Loan Agreement's anti-liquidation covenant (restricts dissolution) is noted but does not affect the mechanical liquidation calculation.
▼ Community Notes